2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells

The endogenous estradiol derivative 2-Methoxyestradiol (2-ME) has shown good and wide anticancer activity but suffers from poor oral bioavailability and extensive metabolic conjugation. However, its sulfamoylated derivative, 2-methoxyestradiol-3,17-O,O-bis-sulfamate (STX140), has superior potential as a therapeutic agent, acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis in cancer cells and possesses much better pharmaceutical properties. This study investigated the antiproliferative and anti-invasive activities of STX140 in both SKMEL-28 naïve melanoma (SKMEL28-P) cells and resistant melanoma cells (SKMEL-28R). STX140 inhibited cell proliferation in the nanomolar range while having a less pronounced effect on human melanocytes. Additionally, STX140 induced cell cycle arrest in the G2/M phase and sub-G1, reduced migration, and clonogenic potential in monolayer models, and inhibited invasion in a 3D human skin model with melanoma cells. Furthermore, STX140 induced senescence features in melanoma and activated the senescence machinery by upregulating the expression of senescence genes and proteins related to senescence signaling. These findings suggest that STX140 may hold potential as a therapeutic agent for melanoma treatment.

[1]  B. Potter,et al.  2-Methoxyestradiol-3,17-O,O-bis-sulfamate inhibits store-operated Ca2+ entry in T lymphocytes and prevents experimental autoimmune encephalomyelitis , 2023, Biochimica et biophysica acta. Molecular cell research.

[2]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[3]  C. Schmitt,et al.  Senescence and cancer — role and therapeutic opportunities , 2022, Nature Reviews Clinical Oncology.

[4]  M. Yousefzadeh,et al.  Cellular senescence: a key therapeutic target in aging and diseases , 2022, The Journal of clinical investigation.

[5]  Jingyu Li,et al.  2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity , 2022, Immunopharmacology and immunotoxicology.

[6]  Hae-June Lee,et al.  2-Methoxyestradiol Inhibits Radiation-Induced Skin Injuries , 2022, International journal of molecular sciences.

[7]  R. Bernards,et al.  Exploiting senescence for the treatment of cancer , 2022, Nature Reviews Cancer.

[8]  L. Alós,et al.  Molecular Markers and Targets in Melanoma , 2021, Cells.

[9]  Stephen L. Brown,et al.  Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy , 2021, Journal of the National Cancer Institute.

[10]  M. Postow,et al.  Combinatorial Approaches to the Treatment of Advanced Melanoma. , 2021, Hematology/oncology clinics of North America.

[11]  M. Herlyn,et al.  Nongenetic Mechanisms of Drug Resistance in Melanoma , 2020, Annual Review of Cancer Biology.

[12]  Ying Xu,et al.  ERK/MAPK signalling pathway and tumorigenesis , 2020, Experimental and therapeutic medicine.

[13]  B. Potter.  SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. , 2018, Journal of molecular endocrinology.

[14]  M. Demaria,et al.  Hallmarks of Cellular Senescence. , 2018, Trends in cell biology.

[15]  Jun Meng,et al.  Characterization and Function of MicroRNA∗s in Plants , 2017, Front. Plant Sci..

[16]  S. Nussberger,et al.  2-Methoxyestradiol Reverses the Pro-Carcinogenic Effect of L-Lactate in Osteosarcoma 143B Cells. , 2017, Cancer genomics & proteomics.

[17]  R. Halaban,et al.  Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  K. Smalley,et al.  Inhibition of proliferation and invasion in 2D and 3D models by 2‐methoxyestradiol in human melanoma cells , 2017, Pharmacological research.

[19]  R. Reis,et al.  Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. , 2016, Pharmacological research.

[20]  Li-xi Yang,et al.  Current Status of Biological Therapies for the Treatment of Metastatic Melanoma. , 2016, Anticancer research.

[21]  B. Bastian,et al.  From melanocytes to melanomas , 2016, Nature Reviews Cancer.

[22]  K. Smetana,et al.  Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness , 2016, Histochemistry and Cell Biology.

[23]  L. Dassa,et al.  Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL , 2016, Nature Communications.

[24]  Mark P Thomas,et al.  The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. , 2015, Anticancer research.

[25]  B. Potter,et al.  Estrogen O-sulfamates and their analogues: Clinical steroid sulfatase inhibitors with broad potential , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  B. Potter,et al.  Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health. , 2015, Journal of medicinal chemistry.

[27]  T. Vos,et al.  Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines , 2014, PloS one.

[28]  Manuel Serrano,et al.  Cellular senescence: from physiology to pathology , 2014, Nature Reviews Molecular Cell Biology.

[29]  B. Price,et al.  DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin , 2014, Proceedings of the National Academy of Sciences.

[30]  Yongzhong Liu,et al.  GADD45 proteins: roles in cellular senescence and tumor development , 2014, Experimental biology and medicine.

[31]  J. Day,et al.  STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice , 2013, PloS one.

[32]  Guohong Zhang,et al.  Targeting MAPK pathway in melanoma therapy , 2013, Cancer and Metastasis Reviews.

[33]  L. Stivala,et al.  The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs. , 2012, Current cancer drug targets.

[34]  G. Peters,et al.  DNA damage signaling triggers degradation of histone methyltransferases through APC/C(Cdh1) in senescent cells. , 2012, Molecular cell.

[35]  K. Smalley,et al.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. , 2011, Biochemical pharmacology.

[36]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[37]  A. Aplin,et al.  Mechanisms of resistance to RAF inhibitors in melanoma , 2011, The Journal of investigative dermatology.

[38]  M. Soengas,et al.  Artificial skin in perspective: concepts and applications , 2011, Pigment cell & melanoma research.

[39]  David F Jarrard,et al.  Therapy-induced senescence in cancer. , 2010, Journal of the National Cancer Institute.

[40]  Michael Ruogu Zhang,et al.  Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence , 2022 .

[41]  B. Potter,et al.  Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate. , 2010, Journal of medicinal chemistry.

[42]  B. Potter,et al.  STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. , 2009, Anticancer research.

[43]  Masayuki Orimo,et al.  A crucial role for adipose tissue p53 in the regulation of insulin resistance , 2009, Nature Medicine.

[44]  H. Tutill,et al.  BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure , 2009, British Journal of Cancer.

[45]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[46]  J. Hansson,et al.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site , 2008, Molecular oncology.

[47]  B. Potter,et al.  STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells , 2008, Clinical Cancer Research.

[48]  C. Supuran,et al.  2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. , 2006, Journal of medicinal chemistry.

[49]  D. DiMaio,et al.  Senescence‐associated β‐galactosidase is lysosomal β‐galactosidase , 2006 .

[50]  S. Steinberg,et al.  Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors , 2006, Cancer biology & therapy.

[51]  B. Potter,et al.  Inhibition of in vitro angiogenesis by 2‐methoxy‐ and 2‐ethyl‐estrogen sulfamates , 2004, International journal of cancer.

[52]  B. Potter,et al.  Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents , 2004, British Journal of Cancer.

[53]  A. Purohit,et al.  The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-α on endothelial and fibroblast cell growth, morphology and apoptosis , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[54]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[55]  H. Takano,et al.  Senescent cells are resistant to death despite low Bcl-2 level , 2001, Mechanisms of Ageing and Development.

[56]  S. Tóth,et al.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.

[57]  E. Wang,et al.  Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. , 1995, Cancer research.

[58]  V. Sondak,et al.  Targeted therapy in melanoma. , 2013, Clinics in dermatology.

[59]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[60]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.